- Home
- OXBR vs KZIA Comparison
OXBR vs KZIA Comparison
Compare OXBR & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OXBR | KZIA |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | Cayman Islands | Australia |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 161.5M |
| IPO Year | 2014 | 1999 |
Fundamental Metrics
Financial Performance| Metric | OXBR | KZIA |
|---|---|---|
| Price | $1.41 | $15.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $16.00 |
| AVG Volume (30 Days) | 19.3K | ★ 1.9M |
| Earning Date | 11-06-2025 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,423,000.00 | $1,199,108.00 |
| Revenue This Year | $497.99 | N/A |
| Revenue Next Year | $42.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.12 | $2.86 |
| 52 Week High | $5.81 | $23.60 |
Technical Indicators
Market Signals| Indicator | OXBR | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 49.71 | 72.51 |
| Support Level | $1.30 | $7.68 |
| Resistance Level | $1.42 | $16.25 |
| Average True Range (ATR) | 0.07 | 2.11 |
| MACD | 0.03 | 0.66 |
| Stochastic Oscillator | 77.33 | 88.76 |
Price Performance
Historical ComparisonAbout OXBR Oxbridge Re Holdings Limited
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.